CELZ
Creative Medical Technology Holdings, Inc.
There isn't enough reported data to score CELZ yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
CELZ Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Weak | |
| Unavailable |
CELZ's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
CELZ PE Valuation
CELZ has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
CELZ Forward outlook
There aren't enough analyst estimates for CELZ to show an outlook.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
CELZ Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.92 | +$1.05 |
| Q2 2026 | -$2.00 | +$1.08 |
| Q1 2026 | -$2.07 | +$1.70 |
| Q4 2025 | -$2.52 | +$1.19 |
CELZ lost $1.92 per share over the past year, a smaller loss than the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over CELZ on earnings quality, reporting a profit while its opponent remains loss making.
CELZ Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $3K | 0% |
| Q4 2024 | $3K | 0% |
| Q4 2023 | $3K | -84% |
| Q3 2023 | $6K | -89% |
| Q4 2022 | $18.6K | -73% |
| Q3 2022 | $55K | +450% |
| Q4 2021 | $67.8K | +287% |
| Q3 2021 | $10K | -87% |
CELZ's revenue has slid since its 2020 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -64859% | -2002 points |
| Q1 2025 | -55349% | N/A |
| Q4 2024 | -62858% | -3797 points |
| Q2 2024 | -20316% | N/A |
| Q4 2023 | -59061% | -25309 points |
| Q3 2023 | -25720% | -23864 points |
| Q4 2022 | -33752% | -31579 points |
| Q3 2022 | -1855% | +6479 points |
CELZ's operating margin was −64859% last quarter, down 5798 points from the same quarter a year ago, near the bottom of its range since 2019.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over CELZ on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
CELZ Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.7M | -$495.7K |
| Q2 2026 | -$1.5M | -$313.5K |
| Q1 2026 | -$1.3M | +$268.2K |
| Q4 2025 | -$1.9M | +$12K |
| Q3 2025 | -$1.2M | -$183K |
| Q2 2025 | -$1.2M | +$310.6K |
| Q1 2025 | -$1.6M | -$694.7K |
| Q4 2024 | -$1.9M | -$54.6K |
CELZ has burned cash in almost every quarter: −$6M over the past year, against −$6M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over CELZ on cash generation, producing positive trailing cash flow while its opponent burns cash.
CELZ Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +80% | +3M shares |
| 1 year | +158% | +4.1M shares |
| 3 years | +373% | +5.3M shares |
CELZ has 7M diluted shares, up 158% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $10,000 |
| Q4 2024 | — |
CELZ hasn't bought back shares in the past year.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over CELZ on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
CELZ Net Leverage
CELZ's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
CELZ Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.3 | Neutral |
| Stochastic | 2.7 | Oversold |
CELZ's weekly RSI is 32 (neutral) and its Stochastic is 3 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
CELZ PE vs Healthcare Sector
CELZ has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
CELZ Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.77 | 19% below |
| 20 week MA | $0.94 | 34% below |
| 50 week MA | $1.62 | 62% below |
| 100 week MA | $2.28 | 73% below |
| 200 week MA | $3.45 | 82% below |
CELZ is in a downtrend: it's below all five of its weekly moving averages, and 82% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over CELZ on trend strength, trading above more of its moving averages.
CELZ Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $225.0 | $19.5 | -91% |
| 2021 | $19.5 | $20.1 | +3.1% |
| 2022 | $20.1 | $3.70 | -82% |
| 2023 | $3.70 | $4.61 | +25% |
| 2024 | $4.61 | $2.31 | -50% |
| 2025 | $2.31 | $2.10 | -9.1% |
| 2026 YTD | $2.10 | $0.62 | -70% |
CELZ has finished lower in four of the last six years. It's down 70% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over CELZ on returns for 2026, with the stronger performance.